Clinical Trial Applications - Stopped: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 3, showing 10 Applications out of 23 total, starting on record 1, ending on 10

# Protocol No Study Title Investigator(s) & Site(s) Date Stopped

1.

ECCT/24/04/04   TNBC
    A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF TOBEMSTOMIG/RO7247669 COMBINED WITH NAB-PACLITAXEL COMPARED WITH   PEMBROLIZUMAB COMBINED WITH NABPACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, PD-L1-POSITIVE, LOCALLY-ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
1. University of Nairobi - Institute of Tropical and Infectious Diseases (Nairobi City county)
2. International Cancer Institute (Nandi county)
3. The Aga Khan University Hospital - Kenya (Nairobi City county)
 
Not recorded View

2.

ECCT/23/12/04   GBT021601 OLE
    An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants with Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial       
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Gertude\'s Children\'s Hospital (Nairobi City county)
2. CENTER FOR RESEARCH IN THERAPEUTIC SCIENCES-STRATHMORE UNIVERSITY MEDICAL CENTER (CREATES (Nairobi City county)
3. KENYA MEDICAL RESEARCH INSTITUTE- CENTER FOR RESPIRATORY DISEASE RESEARCH(CRDR) (Nairobi City county)
4. KEMRI CRDR SIAYA (Siaya county)
 
Not recorded View

3.

ECCT/23/05/05   mRNA-1273-P203
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
2. KEMRI/USAMRD (Kericho county)
3. Victoria Biomedical Research Institute (Kisumu county)
4. Kenya Medical Research Institute/USAMRU (Kisumu county)
5. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
6. KEMRI/ CDC (Kisumu county)
7. KEMRI (Kisumu county)
8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
Not recorded View

4.

ECCT/23/04/07   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr Benhards Ogutu
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. KEMRI/USAMRD (Kericho county)
3. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
4. KAVI Nairobi (Nairobi City county)
5. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
6. KEMRI/ CDC (Kisumu county)
7. KEMRI (Kisumu county)
8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
9. Kenya Medical Research Institute/USAMRU (Kisumu county)
 
Not recorded View

5.

ECCT/23/04/06   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr. Walter Otieno Otieno
Site(s) in Kenya
1. Kenya Medical Research Institute/USAMRU (Kisumu county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. KEMRI/USAMRD (Kericho county)
4. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
5. KEMRI CRDR - Clinical Research Nairobi (Siaya county)
6. KEMRI/ CDC (Kisumu county)
7. KEMRI (Kisumu county)
8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
Not recorded View

6.

ECCT/23/04/01   mRNA-1273-P203
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr Janet Oyieko
Site(s) in Kenya
1. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
2. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
3. KEMRI/USAMRD (Kericho county)
4. Victoria Biomedical Research Institute (Kisumu county)
5. Kenya Medical Research Institute/USAMRU (Kisumu county)
6. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
7. KEMRI/ CDC (Kisumu county)
8. KEMRI (Kisumu county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
Not recorded View

7.

ECCT/23/03/08   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr. Deborah Chepngeno Lang\'at Chepngeno Lang\'at
Site(s) in Kenya
1. KEMRI/USAMRD (Kericho county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. Kenya Medical Research Institute/USAMRU (Kisumu county)
4. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
5. KEMRI/ CDC (Kisumu county)
6. KEMRI CRDR - Clinical Research Nairobi (Siaya county)
7. KEMRI (Kisumu county)
8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
Not recorded View

8.

ECCT/23/03/03   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Prof. Walter Godfrey Jaoko Jaoko
Site(s) in Kenya
1. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. KEMRI/USAMRD (Kericho county)
4. Kenya Medical Research Institute/USAMRU (Kisumu county)
5. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
7. KEMRI/ CDC (Kisumu county)
8. KEMRI (Kisumu county)
9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
 
Not recorded View

9.

ECCT/23/02/07   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr. Maricianah Onono Onono
Site(s) in Kenya
1. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. KEMRI/USAMRD (Kericho county)
4. Kenya Medical Research Institute/USAMRU (Kisumu county)
5. KEMRI CRDR - Clinical Research Nairobi (Siaya county)
6. KEMRI/ CDC (Kisumu county)
7. KEMRI (Kisumu county)
8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
Not recorded View

10.

ECCT/23/02/04   mRNA-1273-P203
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr Victor Mudhune
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. KEMRI/USAMRD (Kericho county)
3. Kenya Medical Research Institute/USAMRU (Kisumu county)
4. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
5. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
7. KEMRI/ CDC (Kisumu county)
8. KEMRI (Kisumu county)
9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
10. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
Not recorded View